Pretreatment PSA levels affects the completion rate of Ra-223 treatment

Abstract The aim of this study was to review our initial experience of using radium 223 (Ra-223) for metastatic castration-resistant prostate cancer (CRPC) and to evaluate whether pretreatment PSA levels correlate with completion of Ra-223 treatment. In addition, we examined change ratios of PSA, AL...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nobuko Utsumi, Hiromasa Kurosaki, Kosei Miura, Hiroki Kitoh, Koichiro Akakura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b21b6bec7d8547c9b0bee33a89f12746
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b21b6bec7d8547c9b0bee33a89f12746
record_format	dspace
spelling	oai:doaj.org-article:b21b6bec7d8547c9b0bee33a89f127462021-12-02T11:39:20ZPretreatment PSA levels affects the completion rate of Ra-223 treatment10.1038/s41598-021-86033-42045-2322https://doaj.org/article/b21b6bec7d8547c9b0bee33a89f127462021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86033-4https://doaj.org/toc/2045-2322Abstract The aim of this study was to review our initial experience of using radium 223 (Ra-223) for metastatic castration-resistant prostate cancer (CRPC) and to evaluate whether pretreatment PSA levels correlate with completion of Ra-223 treatment. In addition, we examined change ratios of PSA, ALP and BAP after the third administration to evaluate the correlation of these change ratios with completion of the subsequent Ra-223 treatment. Forty patients were enrolled in this retrospective study. Ra-223 treatment was considered completed in patients who received five or six administrations. Patient backgrounds and changes in biomarkers were compared between patient groups (complete vs. incomplete Ra-223 treatment). PSA levels before treatment were significantly lower in the complete compared with the incomplete group (cutoff value; 21.7). ALP and BAP levels had decreased after the third administration in the complete group, compared with baseline levels, while levels in the incomplete group had increased. Significant difference was seen in ALP levels, while was not seen in BAP levels between the two groups. Ra-223 treatment should be considered for CRPC with low PSA levels. Changes in PSA and ALP during Ra-223 treatment might provide markers to identify patients likely to complete Ra-223 treatment, with implications for prognosis.Nobuko UtsumiHiromasa KurosakiKosei MiuraHiroki KitohKoichiro AkakuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nobuko Utsumi Hiromasa Kurosaki Kosei Miura Hiroki Kitoh Koichiro Akakura Pretreatment PSA levels affects the completion rate of Ra-223 treatment
description	Abstract The aim of this study was to review our initial experience of using radium 223 (Ra-223) for metastatic castration-resistant prostate cancer (CRPC) and to evaluate whether pretreatment PSA levels correlate with completion of Ra-223 treatment. In addition, we examined change ratios of PSA, ALP and BAP after the third administration to evaluate the correlation of these change ratios with completion of the subsequent Ra-223 treatment. Forty patients were enrolled in this retrospective study. Ra-223 treatment was considered completed in patients who received five or six administrations. Patient backgrounds and changes in biomarkers were compared between patient groups (complete vs. incomplete Ra-223 treatment). PSA levels before treatment were significantly lower in the complete compared with the incomplete group (cutoff value; 21.7). ALP and BAP levels had decreased after the third administration in the complete group, compared with baseline levels, while levels in the incomplete group had increased. Significant difference was seen in ALP levels, while was not seen in BAP levels between the two groups. Ra-223 treatment should be considered for CRPC with low PSA levels. Changes in PSA and ALP during Ra-223 treatment might provide markers to identify patients likely to complete Ra-223 treatment, with implications for prognosis.
format	article
author	Nobuko Utsumi Hiromasa Kurosaki Kosei Miura Hiroki Kitoh Koichiro Akakura
author_facet	Nobuko Utsumi Hiromasa Kurosaki Kosei Miura Hiroki Kitoh Koichiro Akakura
author_sort	Nobuko Utsumi
title	Pretreatment PSA levels affects the completion rate of Ra-223 treatment
title_short	Pretreatment PSA levels affects the completion rate of Ra-223 treatment
title_full	Pretreatment PSA levels affects the completion rate of Ra-223 treatment
title_fullStr	Pretreatment PSA levels affects the completion rate of Ra-223 treatment
title_full_unstemmed	Pretreatment PSA levels affects the completion rate of Ra-223 treatment
title_sort	pretreatment psa levels affects the completion rate of ra-223 treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b21b6bec7d8547c9b0bee33a89f12746
work_keys_str_mv	AT nobukoutsumi pretreatmentpsalevelsaffectsthecompletionrateofra223treatment AT hiromasakurosaki pretreatmentpsalevelsaffectsthecompletionrateofra223treatment AT koseimiura pretreatmentpsalevelsaffectsthecompletionrateofra223treatment AT hirokikitoh pretreatmentpsalevelsaffectsthecompletionrateofra223treatment AT koichiroakakura pretreatmentpsalevelsaffectsthecompletionrateofra223treatment
_version_	1718395721404645376

Pretreatment PSA levels affects the completion rate of Ra-223 treatment

Ejemplares similares